Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 8, 2012, Pages 1306-1313

  Araki, Tomoya ^a   Kono, Yusuke ^a   Ogawara, Ken Ichi ^a   Watanabe, Takaichi ^b   Ono, Tsutomu ^b   Kimura, Toshikiro ^a   Higaki, Kazutaka ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Block copolymer; Enhanced permeability and retention effect; Nanoparticle; Paclitaxel

Indexed keywords

COPOLYMER; CREMOPHOR; LIPOSOME; MACROGOL; MACROGOL POLYLACTIC ACID COPOLYMER; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG RETENTION; IN VITRO STUDY; IN VIVO STUDY; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SPLEEN; TUMOR VOLUME; ZETA POTENTIAL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG CARRIERS; LACTIC ACID; LIVER; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; SPLEEN;

EID: 84864941778     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-0020     Document Type: Article

References (51)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med., 332, 1004-1014 (1995).
2. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm., 235, 179-192 (2002).
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 37, 1590-1598 (2001).
4. Arica Yegin B, Benoît JP, Lamprecht A. Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev. Ind. Pharm., 32, 1089-1094 (2006).
5. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf. B Biointerfaces, 50, 97-103 (2006).
6. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer, 92, 1240-1246 (2005).
7. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release, 72, 191-202 (2001).
8. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J. Control. Release, 126, 122-129 (2008).
9. Sharma A, Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res., 11, 889-896 (1994).
10. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 4, 145-160 (2005).
11. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm., 338, 317-326 (2007).
12. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm. Res., 24, 2402-2411 (2007).
13. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm., 412, 132-141 (2011).
14. Liu F, Liu D. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res., 12, 1060-1064 (1995).
15. Lundberg BB. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol., 49, 16-21 (1997).
16. Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Prog. Lipid Res., 43, 489-533 (2004).
17. Rossi J, Giasson S, Khalid MN, Delmas P, Allen C, Leroux JC. Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. Eur. J. Pharm. Biopharm., 67, 329-338 (2007).
18. Kan P, Chen ZB, Lee CJ, Chu IM. Development of nonionic surfactant/ phospholipid o/w emulsion as a paclitaxel delivery system. J. Control. Release, 58, 271-278 (1999).
19. Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OCM, Maranhão RC. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol., 55, 565-576 (2005).
20. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res., 11, 4136-4143 (2005).
21. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev., 60, 876-885 (2008).
22. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
23. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 65, 271-284 (2000).
24. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev., 47, 113-131 (2001).
25. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res., 53, 3765-3770 (1993).
26. Kawakami S, Opanasopit P, Yokoyama M, Chansri N, Yamamoto T, Okano T, Yamashita F, Hashida M. Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. J. Pharm. Sci., 94, 2606-2615 (2005).
27. Weissig V, Whiteman KR, Torchilin VP. Accumulation of proteinloaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res., 15, 1552-1556 (1998).
28. Yang L, El Ghzaoui A, Li S. In vitro degradation behavior of poly(lactide)-poly(ethylene glycol) block copolymer micelles in aqueous solution. Int. J. Pharm., 400, 96-103 (2010).
29. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol) micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm., 51, 111-118 (2001).
30. Muranaka M, Hirota K, Ono T. PEG-PLA nanoparticles prepared by emulsion solvent diffusion using oil-soluble and water-soluble PEG-PLA. Mater. Lett., 64, 969-971 (2010).
31. Eghbali M, Birnir B, Gage PW. Conductance of GABAA channels activated by pentobarbitone in hippocampal neurons from newborn rats. J. Physiol., 552, 13-22 (2003).
32. + channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. Biochem. Pharmacol., 68, 901-910 (2004).
33. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
34. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release, 103, 405-418 (2005).
35. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci. Rep., 22, 197-224 (2002).
36. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm., 240, 95-102 (2002).
37. Awasthi VD, Garcia D, Goins BA, Phillips WT. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm., 253, 121-132 (2003).
38. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm., 190, 49-56 (1999).
39. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta, 1103, 94-100 (1992).
40. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm., 349, 249-255 (2008).
41. Kang N, Perron ME, Prud'homme RE, Zhang Y, Gaucher G, Leroux JC. Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability. Nano Lett., 5, 315-319 (2005).
42. Schädlich A, Rose C, Kuntsche J, Caysa H, Mueller T, Göpferich A, Mäder K. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm. Res., 28, 1995-2007 (2011).
43. Ogawara K, Un K, Minato K, Tanaka K, Higaki K, Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int. J. Pharm., 359, 234-240 (2008).
44. Lee IH, Park YT, Roh K, Chung H, Kwon IC, Jeong SY. Stable paclitaxel formulations in oily contrast medium. J. Control. Release, 102, 415-425 (2005).
45. Rizzo J, Riley C, von Hoff D, Kuhn J, Phillips J, Brown T. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J. Pharm. Biomed. Anal., 8, 159-164 (1990).
46. Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules, 8, 202-208 (2007).
47. Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm., 65, 309-319 (2007).
48. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release, 74, 295-302 (2001).
49. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelleencapsulated doxorubicin. Br. J. Cancer, 91, 1775-1781 (2004).
50. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer, 97, 170-176 (2007).
51. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br. J. Cancer, 95, 601-606 (2006).